Clemens van Blitterswijk is the founder of RegMed XB and chairs the Scientific Board. He also combines his Professorship at Maastricht University with a Founding Partnership of the LSP-Health Economics Fund (LSP-HEF) of the European health care investment group. He received his PhD degree from Leiden University in 1985 and he worked as an Associate Professor at the Department of Biomaterials at Leiden University. In 1997 he moved to University of Twente and functions as Professor at the Department of Tissue Regeneration. Since 2014 he became University Professor at MERLN institute, Maastricht University.
Van Blitterswijk has acted on numerous national and international advisory boards relating directly to either life and material sciences or to the economic applications thereof. He has held various positions in these organizations including chairman of the Dutch Society for Biomaterials, treasurer of the European Society for Biomaterials, and council member of TERMIS. During his career, he has co-founded multiple biomedical companies and held several functions in these organizations.
Fiona Watt obtained her DPhil, in cell biology, from the University of Oxford and carried out postdoctoral research at MIT. She established her first research group at the Kennedy Institute for Rheumatology and then spent 20 years at the CRUK London Research Institute before moving to Cambridge for 5 years. In 2012 she moved to King's College London to found the Centre for Stem Cells and Regenerative Medicine. She is internationally recognised for her work on stem cells in healthy and diseased tissues and has a research interest in oral cancer. She is a Fellow of the Royal Society and the Academy of Medical Sciences and a Foreign Associate of the National Academy of Sciences. She is currently on secondment as Executive Chair of the Medical Research Council.
Katja Schenke-Layland is an expert in stem cell and extracellular matrix biology as well as diagnostic tool development. One of her main research interests revolves around the role of the extracellular matrix in the establishment of patient-derived three-dimensional in vitro models for functional testing of compounds or medical devices.
Philippe Menasché is a clinical cardiac surgeon at the Hôpital Européen Georges Pompidou, Professor of Thoracic and Cardiovascular Surgery at the University of Paris Descartes, and co-leader of an INSERM (National Institute of Health and Medical Research) team devoted to cell therapy of cardiovascular diseases. He also has a part-time affiliation with the Department of Biomedical Engineering of the University of Alabama in Birmingham. The group has a long-standing interest in stem cells for the treatment of heart failure. While the initial research has focused on the transplantation of skeletal myoblasts, it then moved towards the combination of cardiac progenitors derived from human embryonic stem cells (ESC) with a tissue engineering-based construct. The first-in-man trial testing this cell-loaded patch has now been successfully completed. In parallel, mechanistic studies have unraveled the predominant role of paracrine signaling and, consequently, the group is now shifting its research towards a-cellular cell therapy based on the exclusive use of the secretome with the objective of further streamlining the clinical translatability of this myocardial repair strategy.
René Bindels is as physiologist interested in the regulation of ion transport processes in kidney and small intestine in health and disease. Current projects involve the molecular mechanisms underlying rare tubulopathies and the regulation of the newly identified calcium, magnesium and sodium transporters. He is an elected member of the Academia Europaea. Since 2010 he is the scientific director of the Radboud Institute for Molecular Life Sciences (RIMLS).
Tanja Weil joined the Max Planck Society in 2017 as one of the directors of the Max Planck Institute for Polymer Research (MPIP=, heading the division “Synthesis of Macromolecules”. She studied chemistry (1993–1998) at the TU Braunschweig (Germany) and the University of Bordeaux I (France) and completed her PhD at MPIP under the supervision of K. Müllen. In 2003, she received the Otto Hahn Medal of the Max Planck Society. From 2002 to 2008 she managed different leading positions at Merz Pharmaceuticals GmbH (Frankfurt) from Section Head Medicinal Chemistry to Director of Chemical Research and Development. In 2008 she accepted an Associate Professor position at the National University of Singapore. Tanja Weil joined Ulm University as Director of the Institute of Organic Chemistry III / Macromolecular Chemistry in 2010. She has received numerous competitive funding at both national and international level including a Synergy Grant of the European Research Council (ERC). She serves in many advisory boards and steering committees; she is a member of the senate of the German Research Foundation, a member of the senate of the Leibniz Association and of the Leibniz evaluation panel. Tanja is an associate editor for ACS Nano, a member of the editorial advisory board of J. Am. Chem. Soc. and of the Kuratorium of Angewandte Chemie. Her scientific interests focus on innovative synthesis concepts to achieve functional macromolecules and hybrid materials to solve current challenges in biomedicine and material science.
Thierry Berney obtained his MD at the University of Geneva School of Medicine in Geneva in 1987. He did his postdoctoral work Post-doctoral fellow, at the Diabetes Research Institute and Cell Transplantation Center, University of Miami, Miami, USA, between 1998 and 2001. In 2001, he was back to Geneva to be Director of Pancreas and Islet of Langerhans Transplant Program, Department of Surgery, University of Geneva Hospitals. His current position is full professor at the Department of Surgery.
Frank P. Luyten is board certified Rheumatologist, tenured full Professor and Head of the Division of Rheumatology at the University Hospitals Leuven; Director of the Skeletal Biology & Engineering Research Center, KU Leuven and of Prometheus, the Tissue Engineering Division at the KU Leuven. He obtained his MD, PhD degree and Board Certification in Rheumatology at the University of Ghent, Belgium. He spent his Postdoctoral Training at the National Institute of Dental Research, National Institutes of Health, Bethesda, MD, USA. He became subsequently group leader of the Developmental Biology Unit at the Bone Research Branch, NIDR, NIH, Bethesda, USA. Frank Luyten is also founder, scientific and medical advisor of TiGenix, a Biotech spin-off of the Universities of Leuven and Ghent. He serves as advisor and board member of several biotech companies in the field of Regenerative Medicine.